

24 June 2026

Dear Non-Irish Resident Creditors of Keenova Therapeutics Public Limited Company,

**NOTICE IS HEREBY GIVEN** that, pursuant to an order made by the Irish High Court on Monday 22 June 2026, Keenova Therapeutics Public Limited Company (the “**Company**”) will apply to the Irish High Court on Friday, 17 July 2026 under sections 84 and 85 of the Irish Companies Act 2014 for an order confirming the cancellation of the entire amounts, as at 27 April 2026, standing to the credit of the Company’s Redemption Reserve Account and the Company’s Share Premium Account, in accordance with Article 35 of the Company’s Articles of Association, or such lesser amount as the Irish High Court may determine (the “**Capital Reduction**”).

A capital reduction is balance sheet neutral, in that it reduces one account (being each of the redemption reserve account and the share premium account) and increases another (the retained earnings account (which is a distributable reserve)) by a corresponding amount. As such, the Company’s net asset position will not be directly affected.

The Court has directed that the application for the sanction of the Capital Reduction be heard in the Commercial List of the Irish High Court sitting in the Four Courts, Inns Quay, Dublin 7, Ireland at 11am (Irish time) on Friday, 17 July 2026 (the “**Hearing**”). The Hearing will take place in a hybrid fashion and virtual meeting details are available from the email address below on request.

Any party with such an interest in the Capital Reduction may appear at the Hearing personally or be represented by a solicitor or by counsel. Any such party intending to so appear should give notice in writing to the solicitors for the Company by no later than 5:00 p.m. (Irish time) on Tuesday, 14 July 2026, and any affidavit in support of any such appearance should be filed with the Central Office of the High Court of Ireland, and served on the Solicitors for the Company, by no later than 5:00 p.m. (Irish time) on Tuesday, 14 July 2026.

Should you have any queries please contact the Company’s Corporate Secretary, Mark Tyndall, in writing at Keenova Therapeutics plc, College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.

Yours faithfully,



Mark Tyndall  
EVP, Chief Legal Officer & Corporate Secretary

**KEENOVA THERAPEUTICS PLC**

Keenova Therapeutics public limited company      College Business & Technology Park      +353(0)1 6960000 T  
Cruiserath Road  
Blanchardstown  
Dublin 15  
D15 TX2V  
Ireland

Directors: Paul M. Bisaro (US), Leslie Donato (US), Katina J. Dorton (US), Paul Efron (US), Scott Hirsch (US), Sophia Langlois (Canada), Sigurdur Olafsson (US), Marc Yoskowitz (US), Jonathan Zinman (US)  
Registered in Ireland No: 522227 Registered Office: College Business and Technology Park, Cruiserath Road, Blanchardstown, Dublin 15.

